Standout Papers

Nintedanib for Systemic Sclerosis–Ass... 2008 2026 2014 2020 915
  1. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease (2019)
    Oliver Distler, Kristin B. Highland et al. New England Journal of Medicine
  2. Interstitial Lung Disease in Systemic Sclerosis (2008)
    Nicole Goh, Sujal R. Desai et al. American Journal of Respiratory and Critical Care Medicine
  3. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial (2019)
    Toby M. Maher, Tamera J. Corte et al. The Lancet Respiratory Medicine
  4. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development (2020)
    Paolo Spagnolo, Jonathan A. Kropski et al. Pharmacology & Therapeutics
  5. The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis (2014)
    Philip L. Molyneaux, Michael J. Cox et al. American Journal of Respiratory and Critical Care Medicine
  6. Global incidence and prevalence of idiopathic pulmonary fibrosis (2021)
    Toby M. Maher, Elisabeth Bendstrup et al. Respiratory Research
  7. Interstitial lung diseases (2022)
    Marlies Wijsenbeek, Atsushi Suzuki et al. The Lancet
  8. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis (2022)
    Luca Richeldi, Arata Azuma et al. New England Journal of Medicine
  9. Interstitial Lung Disease (2024)
    Toby M. Maher JAMA
  10. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis (2025)
    Luca Richeldi, Arata Azuma et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 20 from Science/Nature 81 standout
Sub-graph 1 of 21

Citing Papers

Adhesive anti-fibrotic interfaces on diverse organs
2024 StandoutNature
Alveolar fibroblast lineage orchestrates lung inflammation and fibrosis
2024 StandoutNature
5 intermediate papers

Works of Toby M. Maher being referenced

The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial
2018
The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
2018
and 13 more

Author Peers

Author Last Decade Papers Cites
Toby M. Maher 11842 3586 3192 321 14.5k
Kevin K. Brown 11720 4702 2259 188 14.7k
Vincent Cottin 15378 4755 2763 449 18.4k
Roland M. du Bois 15687 6096 4017 129 18.9k
Luca Richeldi 12318 4565 1644 306 17.3k
Martin Kolb 10102 2719 1181 254 14.3k
Demosthenes Bouros 8140 2815 1044 348 11.4k
Kevin R. Flaherty 8703 2852 1096 168 10.4k
Ganesh Raghu 21028 7327 2678 294 25.5k
Ulrich Costabel 15780 8491 1052 389 19.8k
Dominique Valeyre 12578 8075 1075 359 18.1k

All Works

Loading papers...

Rankless by CCL
2026